Galmed Pharmaceuticals (GLMD) Net Cash Flow (2013 - 2026)
Galmed Pharmaceuticals (GLMD) posted quarterly Net Cash Flow of -$2.4 million for Q1 2026, down 2155.17% year-over-year from $116000.0 in Q1 2025, and down 127.33% quarter-over-quarter from $8.7 million in Q4 2025.
Galmed Pharmaceuticals (GLMD) Net Cash Flow (2013 - 2026) Analysis & Trends
Galmed Pharmaceuticals' Net Cash Flow history runs 14 years deep, the most recent figure standing at -$2.4 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 2155.17% year-over-year to -$2.4 million; the TTM figure through Mar 2026 stood at $4.9 million (up 246.49% YoY), while the FY2025 annual figure was $7.4 million, down 10.27% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$2.4 million, down from $8.7 million in the prior quarter.
- The five-year high for Net Cash Flow was $8.7 million in Q4 2025, with the low at -$7.0 million in Q2 2022.
- The 5-year median for Net Cash Flow is -$214000.0 (2023), against an average of -$62823.5.
- The sharpest annual moves came in 2025 and 2026: Net Cash Flow surged 509.64% in 2025, then slumped 2155.17% in 2026.
- Galmed Pharmaceuticals' Net Cash Flow stood at -$2.0 million in 2022, then surged by 167.53% to $1.4 million in 2023, then gained by 3.62% to $1.4 million in 2024, then soared by 509.64% to $8.7 million in 2025, then tumbled by 127.33% to -$2.4 million in 2026.
- Business Quant data shows GLMD's Net Cash Flow at -$2.4 million in Q1 2026, $8.7 million in Q4 2025, and -$1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Galmed Pharmaceuticals | 2.37 Mn | -9.51 Mn | - | -2.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.38 Mn |
| Mar 31, 2026 | -2.38 Mn |
| Dec 31, 2025 | 8.72 Mn |
| Dec 31, 2025 | 8.72 Mn |
| Sep 30, 2025 | -1.65 Mn |
| Sep 30, 2025 | -1.65 Mn |
| Jun 30, 2025 | 197,000.00 |
| Jun 30, 2025 | 197,000.00 |
| Mar 31, 2025 | 116,000.00 |
| Mar 31, 2025 | 116,000.00 |
| Dec 31, 2024 | 1.43 Mn |
| Dec 31, 2024 | 1.43 Mn |
| Sep 30, 2024 | -511,000.00 |
| Sep 30, 2024 | -511,000.00 |
| Jun 30, 2024 | 375,000.00 |
| Jun 30, 2024 | 375,000.00 |
| Mar 31, 2024 | -1.40 Mn |
| Mar 31, 2024 | -1.40 Mn |
| Dec 31, 2023 | 1.38 Mn |
| Dec 31, 2023 | 1.38 Mn |